Boston Scientific’s portfolio of products treat arteriovenous malformations, which is a tangle of abnormal and poorly formed blood vessels and hypervascular tumors. Varian will not acquire any of the Boston Scientific operations, but plans to manufacture and distribute the products.
"This acquisition from Boston Scientific will strengthen Varian's growing position in the high-value interventional oncology segment and is consistent with our long-term strategy to become a global leader in multidisciplinary, integrated cancer solutions," said Dow Wilson, CEO of Varian.
Varian shares were trading down 0.30% at $139.20 Tuesday afternoon.
Karuna Therapeutics Opens Above IPO Price
ImmunoGen To Focus Operations On Mivetuximab Soravtansine Development
See more from Benzinga
- The Boeing 737 MAX Has Been Grounded Since March: How Are Airlines Responding?
- Delta's Solid Q2 Guidance Boosts Airline Stocks
- Faber: T-Mobile, Dish A Step Closer To Finalizing Divestiture
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.